SAN JUAN CAPISTRANO, Calif. & SEOUL, South Korea--(BUSINESS WIRE)--Allegro Ophthalmics, LLC, and Hanmi Pharmaceutical Co., Ltd. today announced that they have entered into a license agreement for Luminate® (ALG-1001), Allegro’s Integrin Peptide Therapy that is currently in multiple Phase 2 studies in the United States for the treatment of vitreo-retinal conditions, in The Republic of Korea and the People’s Republic of China. Hanmi Pharmaceutical also will be making a strategic investment in Allegro that will advance and accelerate the global development program for Luminate.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
